Biochemical and Immunological Assays


CBT scientists are highly experienced and proficient in PCR, RT-PCR, protein and immunoassays. CBT routinely uses ELISA, immunoradio-assays, and fluorescent tag assays for measurement of PD parameters. Frequent problems with these assays are low sensitivity, high background levels and small dynamic range. To overcome these problems, for the past 5 years, CBT has been using the MSD platform for biological test article measurements. Meso Scale Discovery (MSD) platform is based on MULTI-ARRAY® technology, a proprietary combination of electrochemiluminescence detection and patterned arrays. MSD enables the detection of proteins, peptides and antibody biological test articles as well as measurement of PD biomarkers in single and multiplex formats.


Custom assays (developed upon request)

CBT recently developed the following new (more sensitive) biomarkers for liver, kidney, and cardiac toxicity:


·      Cytokines (IL-6, IL-8, IL-10, TNFalpha and G-CSF in non-human primates (NHP)

·      Up to 17-22 cytokine multiplex assays for mice, rats, dogs and NHP

·      Cardiotoxicity Markers (Validated 5-plex assays using MSD cardiac injury panel assay for FABP3, Myl3, Troponin I (skeletal and cardio), and Troponin T in mice, rats, dogs, and non-human primates)

·      Calprotectin and lactoferrin estimation in monkey feces; a newly developed sensitive and non-invasive surrogate biomarker for intestinal inflammation

·      L-FABP and N-GAL (Lipocalin-2) as more sensitive liver toxicity markers

·      Albumin, Lipocalin-2, Osteopontin and KIM-1 4-plex assay as more sensitive nephrotoxicity biomarkers

·      Immunoassays for antibodies (including ADA)